Federal Minister of Health Jens Spahn announces news about the Johnson & Johnson vaccine with colleagues from the federal states after the conference. The live ticker.
- In Germany * the prioritization of the corona vaccine from Johnson & Johnson * falls. (see first report)
- Health Minister Jens Spahn (CDU *) gave a PK on the new developments on Monday. (see first report)
- Experts from Norway * suggest doing without the corona vaccines from J&J and Astrazeneca. (see update from May 10, 12:04 p.m.)
- This news ticker is updated regularly.
Update from May 10, 12:04 p.m.: On the same day that it was announced in Germany that the prioritization for the corona vaccine from Johnson & Johnson was lifted, completely different tones came from Norway. A committee of experts from the Norwegian government and the country’s leading health agency recommend not to use Astrazeneca and Johnson & Johnson’s corona vaccines.
In a report presented on Monday, the committee came to the conclusion after closer investigation that the two funds should not be taken into account in the ongoing vaccination campaign. However, he recommended that the vaccines be made available outside of the campaign. The committee was divided on the conditions for this.
Norwegian experts on Johnson & Johnson corona vaccine waiver
Health Minister Bent Høie said he would now carefully examine the report and use it as a basis for a decision on the use of the two vaccines, along with a recommendation from the FHI Health Institute. His government underlined that the committee viewed the funds as an aggregate as effective vaccines against Covid-19. The recommendation not to use them in the current campaign is based, among other things, on the current infection situation in Norway – which is currently quite good compared to other countries.
Corona vaccination in Germany: Spahn speaks in PK about the question of patents
This ends the press conference.
Update from May 10th, 10:24 am: The willingness to cooperate is very high among all vaccine manufacturers, explains Spahn. The problem is therefore not patents, but production capacities. One wants to support the cooperation for production, says the health minister. “If the USA now exports more vaccine, I would very much welcome that,” said Spahn.
Update from May 10th, 10:22 am: “I can only support and encourage it,” says Spahn when asked about sending mobile vaccination teams to socially disadvantaged areas. “Wherever we can help, we are happy to do so,” explains the Minister of Health. It is now important to reach those who are not actively trying to get a doctor’s appointment or a vaccination appointment.
Spahn explains that the vaccination prioritization at Johnson & Johnson has been lifted
Update from May 10th, 10:20 am: Spahn explains that they are currently working “at full speed” on the digital vaccination card. “In the second half of the second quarter,” he should come. But you want to be sure when it comes to data protection and data security. The paper vaccination certificate remains valid, Spahn clarifies again. “But of course, digital is much more practical,” said the Minister of Health.
Update from May 10, 10.17 a.m.: As of this morning, over 60 percent of people over 60 are already vaccinated. This means that the vaccine has already been determined for them. For the most part, this age group will be vaccinated by early June, explains Spahn. Therefore, in the current situation, it makes sense to make the vaccine from Johnson & Johnson available to younger people “after medical advice and individual risk assessment”.
Update from May 10th, 10.14 am: “Outside there is really a significantly lower risk,” says Spahn about possible relaxation at an incidence below 100. There, the risk of infection is at least ten times lower. However, he warns again against loosening too quickly, the infection numbers in Germany are still too high. According to Spahn, openings should be made “strongly test-supported”, especially when traveling.
Spahn: Side effects at J&J “to be taken seriously, but very rarely”
Update from May 10th, 10:12 am: Side effects are examined and examined very intensively by the Paul Ehrlich Institute, explains Spahn. The experience with Astrazeneca in particular shows that Germany has a good system for monitoring side effects. Patients and doctors report and the Paul Ehrlich Institute examines them.
Update from May 10th, 10:08 a.m.: You have gained important experience by dealing with Astrazeneca. The side effects are very rare, but should be taken very seriously. Especially in the current phase, when almost all over 60-year-olds are vaccinated or have a vaccination appointment, the existing vaccination doses from Johnson & Johnson should be made accessible to everyone by lifting the vaccination prioritization, explains Spahn.
Update from May 10, 10:05 a.m.: There are reports on cerebral vein thromboses from other countries on the corona vaccine from Johnson & Johnson *, Spahn begins. Therefore, the federal and state health ministers have decided on this recommendation. The side effects are “to be taken seriously, but very rare”. As with Astrazeneca, the prioritization is canceled. After medical advice, anyone can decide to be vaccinated with this vaccine.
Next vaccine turnaround: J&J in Germany, especially for people over 60
First report from May 10th: Berlin – The corona vaccine * from Johnson & Johnson will generally be used in Germany for people over 60 in the future. After medical information, however, younger people can also decide, the federal and state health ministers decided, as the German press agency learned on Monday. The prioritization for this vaccine is canceled in medical practices and company doctors at the same time. This will be done from this Monday. Health Minister Jens Spahn commented on Monday.
As stated in the resolution of the Conference of Health Ministers, ministers take “the reported cases of cerebral vein thrombosis in connection with vaccination with the Johnson & Johnson vaccine” seriously. Similar to the Astrazeneca vaccine, such serious side effects were very rare.
Against this background, the Standing Vaccination Commission proposed the recommendation to vaccinate the preparation “for people aged> 60”. As with vaccinations with the Astrazeneca vaccine, vaccination should also be possible for under-60s after medical information and an individual risk analysis. The special thing about the vaccine from Johnson & Johnson is that, unlike the corona vaccines * that have been used to date, only one syringe is sufficient for full protection. (ph / dpa) * Merkur.de is an offer from IPPEN.MEDIA
